<code id='FD3DA41EB8'></code><style id='FD3DA41EB8'></style>
    • <acronym id='FD3DA41EB8'></acronym>
      <center id='FD3DA41EB8'><center id='FD3DA41EB8'><tfoot id='FD3DA41EB8'></tfoot></center><abbr id='FD3DA41EB8'><dir id='FD3DA41EB8'><tfoot id='FD3DA41EB8'></tfoot><noframes id='FD3DA41EB8'>

    • <optgroup id='FD3DA41EB8'><strike id='FD3DA41EB8'><sup id='FD3DA41EB8'></sup></strike><code id='FD3DA41EB8'></code></optgroup>
        1. <b id='FD3DA41EB8'><label id='FD3DA41EB8'><select id='FD3DA41EB8'><dt id='FD3DA41EB8'><span id='FD3DA41EB8'></span></dt></select></label></b><u id='FD3DA41EB8'></u>
          <i id='FD3DA41EB8'><strike id='FD3DA41EB8'><tt id='FD3DA41EB8'><pre id='FD3DA41EB8'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:32
          Stain of a biopsy specimen of a rhabdoid tumor -- health coverage from STAT
          Stain of a biopsy specimen of a rhabdoid tumor. Wikimedia Commons

          Most targeted cancer drugs work like tranquilizer darts, snaring an overzealous gene that has spurred the cell into murderously rapid growth.

          But many tumors don’t have a hyperactive gene. Like the mayhem in “Cat in the Hat,” they are enabled by parental absence. They grow because the genes that are meant to provide discipline, guiding the activity of other genes or self-destructing a cell whose DNA is too damaged, are broken or missing.

          advertisement

          These tumors have bedeviled researchers for decades. Restoring or fixing a protein is far harder than breaking it. And that’s bad news for humanity: Cancer is far more likely to be caused by such “tumor-suppressor” genes than by one gene run amok. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more
          Diversity in clinical trials starts with building trust, experts say
          Diversity in clinical trials starts with building trust, experts say

          SilasBuchanan,CEOofOurHealthyCommunity,speaksonapanelaboutdemocratizingclinicaltrialsattheMilkenInst

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          3 hurdles to bringing medical devices to the U.S. market

          Medicaldeviceshavehistoricallybeenseenashavingfasterpathstomarketthantheirpharmacologicalcounterpart